FDA Awareness Letters Have Impact, Allergan Counsel Says

Law360, New York (August 16, 2013, 2:19 PM EDT) -- An Allergan Inc. attorney on Friday told a U.S. Food and Drug Administration panel that the agency's awareness letters alerting medical providers of the possible use of counterfeit or unapproved pharmaceuticals has brought in business for the company and persuaded some providers to use legitimate suppliers.

Allergan counsel Bryan E. Smith told a panel of the FDA's Risk Communication Advisory Committee that the letters — sent to doctors and medical clinics suspected of using drugs from unregistered and potentially counterfeit drug providers — has convinced some...
To view the full article, register now.